{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:40:44Z","timestamp":1794109244699,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.parkreldis.2026.108995","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:29:18Z","timestamp":1790519358000},"page":"108995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Short-term efficacy and safety of tavapadon for Parkinson's disease: An exploratory systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2231-9104","authenticated-orcid":false,"given":"Th\u00e9o Santana","family":"Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4274-8008","authenticated-orcid":false,"given":"Pedro Sandes","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8837-2678","authenticated-orcid":false,"given":"Maria Eduarda","family":"Pires Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6887-2143","authenticated-orcid":false,"given":"Luiz Ricardo","family":"de Sousa Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0740-2932","authenticated-orcid":false,"given":"Paulo Rafael","family":"Grassi Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8776-1516","authenticated-orcid":false,"given":"Theo Cardoso","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1959-3224","authenticated-orcid":false,"given":"Marcos Paulo Rodrigues","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6889-7088","authenticated-orcid":false,"given":"Michelle","family":"Andrade Nascimento Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6103-8420","authenticated-orcid":false,"given":"Oc\u00edlio Ribeiro","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3787-1318","authenticated-orcid":false,"given":"Guilherme Garcia","family":"Nery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1535-1498","authenticated-orcid":false,"given":"Philip George Glass","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2026.108995_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10423","key":"10.1016\/j.parkreldis.2026.108995_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2026.108995_bib24","series-title":"Parkinson Disease: a Public Health Approach","year":"2022"},{"issue":"4","key":"10.1016\/j.parkreldis.2026.108995_bib3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2174\/1871527322666230331121028","article-title":"Rationale and development of Tavapadon, a D1\/D5-Selective partial dopamine agonist for the treatment of Parkinson's disease","volume":"23","author":"Bezard","year":"2024","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"issue":"10423","key":"10.1016\/j.parkreldis.2026.108995_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson's disease","volume":"403","author":"Foltynie","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.parkreldis.2026.108995_bib20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s10072-023-07254-1","article-title":"Impulse control disorders in Parkinson's disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis","volume":"45","author":"Soileau","year":"2024","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108995_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","article-title":"Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions","volume":"8","author":"Dong-Chen","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"9","key":"10.1016\/j.parkreldis.2026.108995_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13090290","article-title":"Emerging clinical role of Tavapadon, a novel dopamine partial agonist, in the treatment of Parkinson's disease","volume":"13","author":"Kaye","year":"2025","journal-title":"Diseases"},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108995_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40120-018-0114-z","article-title":"Phase 1 Parkinson's disease studies show the dopamine D1\/D5 agonist PF-06649751 is safe and well tolerated","volume":"7","author":"Sohur","year":"2018","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108995_bib22","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1038\/s41467-022-30929-w","article-title":"Ligand recognition and biased agonism of the D1 dopamine receptor","volume":"13","author":"Teng","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.parkreldis.2026.108995_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1474-4422(26)00215-2","article-title":"Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial","volume":"25","author":"Fernandez","year":"2026","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2026.108995_bib8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jamaneurol.2026.0577","article-title":"Tavapadon as adjunctive treatment for parkinson disease: the TEMPO-3 randomized clinical trial","volume":"83","author":"Fernandez","year":"2026","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2026.108995_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jamaneurol.2026.0590","article-title":"Fixed-dose tavapadon for early parkinson disease: a randomized clinical trial","volume":"83","author":"Pahwa","year":"2026","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2026.108995_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420911296","article-title":"PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial","volume":"13","author":"Riesenberg","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.parkreldis.2026.108995_bib14","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2026.108995_bib10","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.4","year":"2024"},{"key":"10.1016\/j.parkreldis.2026.108995_bib21","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trial","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108995_bib18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/mds.20914","article-title":"Minimal clinically important change on the unified Parkinson's Disease rating scale","volume":"21","author":"Schrag","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2026.108995_bib23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/NDT.S60061","article-title":"Nonergot dopamine-receptor agonists for treating Parkinson's disease \u2013 a network meta-analysis","volume":"10","author":"Thorlund","year":"2014","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"12","key":"10.1016\/j.parkreldis.2026.108995_bib11","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the motor examination part of MDS-UPDRS","volume":"21","author":"Horv\u00e1th","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108995_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0163-7258(99)00029-7","article-title":"Dopamine receptors--physiological understanding to therapeutic intervention potential","volume":"84","author":"Emilien","year":"1999","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108995_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.parkreldis.2026.108995_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00002018-200326060-00005","article-title":"Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis","volume":"26","author":"Etminan","year":"2003","journal-title":"Drug Saf."},{"key":"10.1016\/j.parkreldis.2026.108995_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson's disease","volume":"23","author":"Mamikonyan","year":"2008","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802026008229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802026008229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:33:43Z","timestamp":1793694823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802026008229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":24,"alternative-id":["S1353802026008229"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108995","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term efficacy and safety of tavapadon for Parkinson's disease: An exploratory systematic review and meta-analysis of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108995"}}